Nav: Home

Antibiotic therapy for nearly 1 in 4 adults with pneumonia does not work

May 21, 2017

ATS 2017, WASHINGTON, DC -- Approximately one in four (22.1 percent) adults prescribed an antibiotic in an outpatient setting (such as a doctor's office) for community-acquired pneumonia does not respond to treatment, according to a new study presented at the 2017 American Thoracic Society International Conference.

"Pneumonia is the leading cause of death from infectious disease in the United States, so it is concerning that we found nearly one in four patients with community-acquired pneumonia required additional antibiotic therapy, subsequent hospitalization or emergency room evaluation," said lead author James A. McKinnell, MD, an LA BioMed (Los Angeles, CA) lead researcher and infectious disease specialist. "The additional antibiotic therapy noted in the study increases the risk of antibiotic resistance and complications like C. difficile ("C diff") infection, which is difficult to treat and may be life-threatening, especially for older adults."

Dr. McKinnell and colleagues conducted this study because current community-acquired pneumonia guidelines from the American Thoracic Society and the Infectious Disease Society of America, published in 2007, provide some direction, but large-scale, real-world data are needed to better understand and optimize antibiotic choices and to better define clinical risk factors that may be associated with treatment failure.

The researchers examined databases containing records for 251,947 adult patients who were treated between 2011 and 2015 with a single class of antibiotics (beta-lactam, macrolide, tetracycline, or fluoroquinolone) following a visit to their physician for treatment for community-acquired pneumonia. The scientists defined treatment failure as either the need to refill antibiotic prescriptions, antibiotic switch, ER visit or hospitalization within 30 days of receipt of the initial antibiotic prescription. The total antibiotic failure rate was 22.1 percent, while patients with certain characteristics -- such as older age, or having certain other diseases in addition to pneumonia -- had higher rates of drug failure. After adjusting for patient characteristics, the failure rates by class of antibiotic were: beta-lactams (25.7 percent), macrolides (22.9 percent), tetracyclines (22.5 percent), and fluoroquinolones (20.8 percent).

"Our findings suggest that the community-acquired pneumonia treatment guidelines should be updated with more robust data on risk factors for clinical failure," said Dr. McKinnell. "Our data provide numerous insights into characteristics of patients who are at higher risk of complications and clinical failure. Perhaps the most striking example is the association between age and hospitalization: Patients over the age of 65 were nearly twice as likely to be hospitalized compared to younger patients when our analysis was risk adjusted and nearly three times more likely in unadjusted analysis. Elderly patients are more vulnerable and should be treated more carefully, potentially with more aggressive antibiotic therapy."

Dr. McKinnell also stated that his study found substantial regional variations in treatment outcomes, which are not addressed in a specific way in the community-acquired pneumonia guidelines. In addition, the study showed that thousands of patients who suffer from other conditions - such as chronic obstructive pulmonary disease, cancer or diabetes - were not treated with combination antibiotic therapy or respiratory fluoroquinolone, as the guidelines recommend.

"While certain aspects of the guidelines need to be updated, some prescribers also have room for improvement and should implement the current guidelines," he concluded.
-end-
Abstract 8450

Clinical Predictors of Antibiotic Failure in Adult Outpatients with Community-Acquired Pneumonia

Authors: J. McKinnell1, P. Classi2, P. Blumberg3, S. Murty3, G. Tillotson2; 1UCLA - Los Angeles, CA/US, 2Cempra Pharmaceuticals - Chapel Hill, NC/US, 3Xcenda LLC - Palm Harbor, FL/US

Rationale: Antibiotic failure for community-acquired pneumonia (CAP) is associated with substantial morbidity and mortality and results in significant medical expenditures. Current CAP guidelines provide some direction on antibiotic selection in the outpatient setting, but large-scale, "real-world" data are needed to better understand and optimize antibiotic choice and to better define clinical risk factors which may be associated with treatment failure.

Methods: We conducted a retrospective cohort analysis of outpatient CAP from MarketScan® Commercial & Medicare Supplemental Databases between 2011 and 2015. Patients were ?18 years old and received antibiotic treatment following an outpatient visit for CAP (based on ICD-9-CM codes). Patients were required to have a monotherapy antibiotic prescription claim for one of the following drug classes: macrolides, fluoroquinolones, beta-lactams or tetracyclines. Treatment failure was defined as any of the following CAP related events occurring within 30 days of initial antibiotic fill: antibiotic refill, antibiotic switch, ER visit or hospitalization. A multivariable logistic regression model was employed to determine predictors of treatment failure.

Results: 251,947 adult outpatients met inclusion criteria. Mean age was 52.2 years with 47.7% male and 21.5% Medicare enrollees. The majority of patients were prescribed azithromycin (n=101,492, 40.3%) followed by levofloxacin (n=95,019, 37.7%). Total antibiotic failure rate was 22.1% (n=55,741/251,947) and comprised of: antibiotic refill (n=11,493/55,741, 20.6%), antibiotic switch (n=39,397/55,741, 70.7%), ER visit (n=1,835/55,741, 3.3%) and hospitalization (n=3,015/55,741, 5.4%). Multivariate predictors of antibiotic failure included: diagnosis of pneumococcal pneumonia (p<0.02), older age (p<0.0001), and female gender (p<0.0001). Various comorbidities were associated with higher rates of antibiotic failure including: hemiplegia/paraplegia (OR=1.33 [1.17-1.51]), rheumatologic disease (OR=1.28 [1.21-1.35]), chronic pulmonary disease (OR=1.25 [1.21-1.29]), cancer (OR=1.14 [1.09-1.18]), diabetes (OR=1.07 [1.04-1.10]) and asthma (OR=1.05 [1.01-1.10]). With each increasing Charlson Comorbidity Index (CCI) score, the probability of antibiotic failure increased (OR=1.16 [1.13-1.20] for CCI=1, OR=1.22 [1.18-1.26] for CCI=2, OR=1.44 [1.39-1.49] for CCI ?=3) compared to CCI=0. After adjusting for baseline patient characteristics, beta-lactams were associated with the highest antibiotic failure rate (25.7%), followed by macrolides (22.9%), tetracyclines (22.5%), and fluoroquinolones (20.8%).

Conclusion: Approximately one in four adult outpatients prescribed antibiotic monotherapy for CAP fail treatment. We identified multiple predictors of failure and clinically meaningful differences between antibiotic classes. Prescribers should be aware of those CAP patients at risk for poor outcomes and consider these factors to guide a comprehensive treatment plan, including more appropriate antibiotic treatment.

FOR MORE INFORMATION, CONTACT:

Dacia Morris
dmorris@thoracic.org
ATS Office 212-315-8620 (until May 17)
Cell Phone 917-561-6545

Session: A95 Acute Pneumonia: Clinical Studies
Abstract Presentation Time: Sunday, May 21, 3:15 p.m. ET
Location: West Salon G-1 (South Building, Street Level), Walter E. Washington Convention Center

American Thoracic Society

Related Pneumonia Articles:

Antibiotic therapy for nearly 1 in 4 adults with pneumonia does not work
Approximately one in four (22.1 percent) adults prescribed an antibiotic in an outpatient setting (such as a doctor's office) for community-acquired pneumonia does not respond to treatment, according to a new study presented at the 2017 American Thoracic Society International Conference.
Discovery may help patients beat deadly pneumonia
Researchers have identified a hormone that helps fight off a severe form of bacterial pneumonia, and that discovery may offer a simple way to help vulnerable patients.
Community-acquired pneumonia can spread year-round
New research indicates that community-acquired pneumonia should not be regarded as a seasonal disease, as it occurs throughout all seasons; however, the pathogens that cause the condition are clearly subject to seasonal variations.
Among antidementia drugs, memantine is associated with the highest risk of pneumonia
A recent study from the University of Eastern Finland shows that among users of antidementia drugs, persons using memantine have the highest risk of pneumonia.
Good news for kids recovering from complex pneumonia
In some good news for families of children recovering from complex pneumonia, doctors recommend in a study published by Pediatrics it's better to send kids home from the hospital with oral instead of intravenous antibiotics.
Ventilator-associated pneumonia rates remain stable, substantial
In a study published online by JAMA, Mark L. Metersky, M.D., of the UConn School of Medicine, Farmington, and colleagues analyzed trends in Medicare Patient Safety Monitoring System ventilator-associated pneumonia rates from 2005 through 2013.
Pneumonia rates linked to hospital ventilators have not dropped
Contrary to data published by the Centers for Disease Control, ventilator-associated pneumonia rates in hospital intensive care units have not declined significantly since 2005, according to a new study out of the University of Connecticut School of Medicine.
Vitamin E may prevent pneumonia in nonsmoking elderly men
Administration of 50 mg per day of vitamin E decreased the risk of pneumonia in elderly male smokers by 72 percent after they quit smoking, according to a paper published in Clinical Interventions in Aging.
New model sheds light on secondary bacterial pneumonia
For years, researchers have known that the bacteria Staphylococcus aureus can trigger severe, sometimes deadly secondary bacterial pneumonia, in some people who are subsequently infected with influenza A virus, but scientists have not known exactly how this happens.
Pneumonia discovery may offer way to boost body's defenses
The finding may offer a new way for doctors to boost patients' ability to fight off the life-threatening infection as bacteria become more and more resistant to antibiotics.

Related Pneumonia Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Digital Manipulation
Technology has reshaped our lives in amazing ways. But at what cost? This hour, TED speakers reveal how what we see, read, believe — even how we vote — can be manipulated by the technology we use. Guests include journalist Carole Cadwalladr, consumer advocate Finn Myrstad, writer and marketing professor Scott Galloway, behavioral designer Nir Eyal, and computer graphics researcher Doug Roble.
Now Playing: Science for the People

#530 Why Aren't We Dead Yet?
We only notice our immune systems when they aren't working properly, or when they're under attack. How does our immune system understand what bits of us are us, and what bits are invading germs and viruses? How different are human immune systems from the immune systems of other creatures? And is the immune system so often the target of sketchy medical advice? Those questions and more, this week in our conversation with author Idan Ben-Barak about his book "Why Aren't We Dead Yet?: The Survivor’s Guide to the Immune System".